|
|
|
| Clinical study of hyperthermia combined with Aescinate Sodium for Injection in treating pneumonia-like pleural effusion |
| WANG Ziting1 ZHAO Fang2 JIANG Guorong3 WANG Jian1 CHEN Jing2 TAI Yanmiao1 SUN Yancheng1 |
1.Department of Respiratory, Baoding Second Central Hospital, Hebei Province, Baoding 072750, China;
2.the Second Department of Respiratory, Baoding Second Central Hospital, Hebei Province, Baoding 072750, China;
3.CT Room, Baoding Second Central Hospital, Hebei Province, Baoding 072750, China |
|
|
|
Abstract Objective To investigate the clinical efficacy and safety of hyperthermia combined with Aescinate Sodium for Injection in the treatment of pneumonia-like pleural effusion. Methods A total of 120 patients with pneumonic pleural effusion admitted to Baoding Second Central Hospital of Hebei Province from July 2016 to July 2018 were selected. The patients were divided into control group (60 cases) and research group (60 cases) by random number table method. The control group was treated with Sodium Aescinate for Injection, and the research group was combined with deep hyperthermia on the basis of the treatment in the control group. Both groups were given 2 courses of treatment, and 5 days was one course of treatment. The clinical effects, absorption time of pleural effusion, antipyretic time and hospitalization time in two groups were evaluated and compared. Pulmonary function indexes, including forced vital capacity (FVC) and forced expiratory volume in the first second (FEV1) were compared between the two groups before and after treatment. The adverse reactions during treatment were compared between the two groups. Results The total effective rate of the study group was higher than that of the control group, and the difference between the two groups was statistically significant (P ＜ 0.05). The absorption time of pleural effusion, antipyretic time and hospitalization time in the research group were significantly shorter than those in the control group, and the differences were statistically significant (all P ＜ 0.05). After treatment, FVC and FEV1 were significantly increased in the two groups compared with those before treatment, and the increase degree in the study group was greater than that in the control group (P ＜ 0.05). During the treatment, there was no statistically significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Hyperthermia combined with Aescinate Sodium for Injection has obvious therapeutic effect on pneumonia-like pleural effusion, and can shorten the treatment time, with good safety.
|
|
|
|
|
|
[1] 穆鹏，胡方芳，袁军.肺炎并类肺炎性胸腔积液抗感染诊疗1例[J].江苏医药，2018，44（3）：352-354.
[2] 李珊珊，黄芩，胡月新，等.人血白蛋白在类肺炎性胸腔积液联合治疗中的临床应用[J].临床医学研究与实践，2016，1（13）：46-47.
[3] 赵爽.中心静脉导管置管闭式引流术治疗类肺炎性胸腔积液临床探讨[J].中国社区医师，2017，33（34）：93-94.
[4] 黄琪述，陈仲勤，梁景强，等.注射用七叶皂苷钠联合联合糖皮质激素治疗类肺炎性胸腔积液的临床效果[J].现代诊断与治疗，2016，27（10）：1817-1818.
[5] 梁煜，林文苑，梁卓林，等.应用洛铂体腔热灌注联合体外高频深部热疗治疗晚期恶性胸腹水的疗效观察[J].中国实用医药，2018，13（20）：16-18.
[6] 钟南山，刘又宁.呼吸病学[M].2版.北京：人民卫生出版社，2012：245-260.
[7] 叶任高，陆再英.内科学[M].6版.北京：人民卫生出版社，2004：108-110.
[8] 李娟.降钙素原的测定在类肺炎性胸腔积液诊断中的价值[J].临床医学研究与实践，2017，2（22）：71-72.
[9] 裴培，刘志.急诊社区获得性肺炎患者中类肺炎性胸腔积液的危险因素分析[J].中国医科大学学报，2017，46（7）：653-655.
[10] 刘洪彬.类肺炎性胸腔积液70例临床分析[J].中国社区医师：医学专业，2013，15（7）：74-75.
[11] 梁世文.中心静脉导管置管闭式引流治疗类肺炎性胸腔积液临床观察[J].临床合理用药杂志，2013，6（10）：20，24.
[12] 刘顺良，王文森，康跃展.七叶皂苷钠的药效学与临床应用研究进展[J].中国临床药学杂志，2003，12（6）：386-387.
[13] 张会钦，薛婷，王沛钦，等.胸腔灌注化疗联合深部热疗治疗恶性胸腔积液[J].世界最新医学信息文摘，2017， 17（98）：185.
[14] 尹静静，薛枫，佟海霞，等.对内生场深部热疗治疗恶性胸腹水患者的临床护理[J].中华保健医学杂志，2018， 20（1）：61-63.
[15] 闫敬格.体外高频深部热疗治疗恶性胸腔积液的临床疗效观察[J].临床医药文献电子杂志，2017，4（27）：5164.
[16] 张凤宇，郭文新，裴树丰，等.注射用七叶皂苷钠联合抗感染治疗类肺炎性胸腔积液15例临床观察[J].河北中医，2011，33（1）：95-96.
[17] 叶慧青，钟妙文，杨劲松.深部热疗联合参芪扶正注射液治疗恶性胸腔积液疗效观察[J].深圳中西医结合杂志，2016，26（17）：25-27.
[18] 丁婷，欧阳瑶.类肺炎性胸腔积液所致反应性浆细胞增多症1例[J].中国实用医药，2012，7（20）：188-189.
[19] 宋瑞红.类肺炎性胸腔积液68例临床分析[J].实用医学杂志，2009，25（18）：3105-3107.
[20] 侯广平.七叶皂苷钠的主要临床应用研究现状[J].中国药师，2006，9（1）：57-58.
[21] 洪月光，何宁一，张敬，等.中药外敷结合腔内灌注及深部热疗治疗恶性胸腔积液40例[J].中国中医药现代远程教育，2015，13（9）：38-40. |
|
|
|
